5913 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1735)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2526)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5913)
  2. GSK Faculty (5696)
  3. Department of Medicine (4258)
  4. Department of Pathology and Laboratory Medicine (3036)
  5. Tow Center for Developmental Oncology (TCDO) (2612)
  6. Solid Tumor Oncology Division (2599)

More Groups

People
  1. Marc Ladanyi (1326)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (119)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (262)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (757)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5913)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • T-cell depleted allografts from unrelated donors confer a low risk of relapse on patients with hematologic malignancies
    Meeting Abstract

    Jakubowski, A. A.; Small, T.; Barker, J. N.; Boulad, F.; Castro-Malaspina, H. R.; Hsu, K. C.; Kernan, N.; Koehne, G.; Perales, M. A.; Prockop, S.; more...
    Biology of Blood and Marrow Transplantation (2010)

    Fulltext@MSK | Save
  • Temporary licensing of hyporesponsive NK cells following allogeneic HCT is not affected by T-cells in the stem cell allograft
    Meeting Abstract

    Tarek, N.; Yu, J.; Venstrom, J. M.; Hsu, K. C.
    Biology of Blood and Marrow Transplantation (2010)

    Fulltext@MSK | Save
  • The Memorial Sloan-Kettering experience with allogeneic stem cell transplantation for T cell non-Hodgkins lymphomas
    Meeting Abstract

    Goldberg, J. D.; Chou, J.; Jakubowski, A. A.; Arcila, M. E.; Teruya-Feldstein, J.; Horwitz, S.; Barker, J. N.; Boulad, F.; Castro-Malaspina, H. R.; Hsu, K.; more...
    Biology of Blood and Marrow Transplantation (2010)

    Fulltext@MSK | Save
  • Vandetanib (VAN) in locally advance or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA)
    Meeting Abstract

    Wells, S. A.; Robinson, B. G.; Gagel, R. F.; Dralle, H.; Fagin, J. A.; Santoro, M.; Baudin, E.; Vasselli, J. R.; Read, J.; Schlumberger, M.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI)
    Meeting Abstract

    Oxnard, G. R.; Riely, G. J.; Arcila, M. H.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • EGFR mutations in men and cigarette smokers with lung adenocarcinoma
    Meeting Abstract

    Pietanza, M.; D'Angelo, S. P.; Johnson, M. L.; Paik, P. K.; Riely, G. J.; Miller, V. A.; Zakowski, M. F.; Rusch, V. W.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma
    Meeting Abstract

    Nghiemphu, P. L.; Omuro, A. M.; Cloughesy, T.; Mellinghoff, I. K.; Norden, A. G.; Nguyen, L. T.; Rajangam, K.; Wen, P. Y.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis
    Meeting Abstract

    Mitsiades, N.; Antipin, Y.; Reva, B.; Schultz, N.; Danila, D. C.; Sung, C. C.; Anand, A.; Sander, C.; Scher, H. I.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Initial results of LC-MAP: An institutional program to routinely profile tumor specimens for the presence of mutations in targetable pathways in all patients with lung adenocarcinoma
    Meeting Abstract

    Kris, M. G.; Lau, C. Y.; Ang, D.; Brzostowski, E.; Riely, G. J.; Rusch, V. W.; Jhanwar, S.; Lash, A.; Zakowski, M. F.; Ladanyi, M.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV)
    Meeting Abstract

    Khasraw, M.; Abrey, L. E.; Lassman, A. B.; Hormigo, A.; Nolan, C.; Gavrilovic, I. T.; Mellinghoff, I. K.; Reiner, A. S.; DeAngelis, L. M.; Omuro, A. M.
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save